EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has announced a significant milestone with the Japanese Patent Office issuing a Notice of Allowance for its ExoPTEN patent, marking a key step in protecting its innovative therapy aimed at nerve regeneration for spinal cord injuries. The patent underscores the novelty of NurExone’s technology, which is part of an extensive intellectual property portfolio and licensed exclusively from the Technion. With patents also granted in the United States and Russia, and the progress toward clinical trials, the company is poised to expand its market potential significantly, especially in the vital Asian markets.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
